FDA Grants Approval to Abbreviated New Drug Application for Leuprolide Acetate Injection in Advanced Prostate Cancer

Article

An abbreviated new drug application was granted approval by the FDA for leuprolide acetate injection for patients with advanced prostate cancer.

The FDA has granted approval to an abbreviated new drug application for leuprolide acetate injection for patients with advanced prostate cancer, according to a press release from Amneal Pharmaceuticals.1

This injection is indicated for palliative treatment in patients with advanced prostate cancer. The abbreviated application is used for the review and approval of generic drugs.2 If the product is approved, manufacturing and marketing for it may begin. This will allow the drug to be produced as a safe, effective, and lower-cost alternative than the brand-name drug.

“We are making tremendous progress expanding our injectables business. This latest new product is another key therapeutic for the institutional market and another complex, high-value launch by the team,” Harsher Singh, senior vice president for Amneal Biosciences, said in the press release.

References

  1. Amneal receives FDA approval for leuprolide acetate injection. News release. Amneal Pharmaceuticals. November 2, 2022. Accessed November 2, 2022. https://yhoo.it/3zChiuA
  2. Abbreviated new drug application (ANDA). News release. FDA. Accessed November 2, 2022. https://bit.ly/3h9wkC1
Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content
A combined genomic and histological analysis within trial datasets demonstrates a sound tumor evaluation strategy for patients with prostate cancer.

Tool Combining Genomics, AI May Predict Future Prostate Cancer Recurrence

Roman Fabbricatore
July 23rd 2024
Article

A combined genomic and histological analysis within trial datasets demonstrates a sound tumor evaluation strategy for patients with prostate cancer.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Developers plan to submit data from the ARANOTE trial to global regulatory health authorities to expand indications for darolutamide in metastatic HSPC.

Darolutamide Combo Improves Radiological PFS in Metastatic HSPC

Russ Conroy
July 17th 2024
Article

Developers plan to submit data from the ARANOTE trial to global regulatory health authorities to expand indications for darolutamide in metastatic HSPC.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Judd W. Moul, MD;Kostantinos E. Morris, BS
May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

In a phase 1 trial, City of Hope’s CAR T-cell therapy showed minimal adverse effects and promising therapeutic activity for advanced prostate cancer.

CAR T-Cell Therapy Demonstrates Promising Results for mCRPC

Roman Fabbricatore
June 27th 2024
Article

In a phase 1 trial, City of Hope’s CAR T-cell therapy showed minimal adverse effects and promising therapeutic activity for advanced prostate cancer.

Compared with cognitively-defined and hemigland contours, AI-assisted cancer contours delivered a greater balanced accuracy rate.

AI-Assisted Contours Exhibit High Accuracy in Evaluating Prostate Cancer

Roman Fabbricatore
June 20th 2024
Article

Compared with cognitively-defined and hemigland contours, AI-assisted cancer contours delivered a greater balanced accuracy rate.